CASC15 gene polymorphisms reduce neuroblastoma risk in Chinese children
Metrics: PDF 407 views | HTML 936 views | ?
Jiao Zhang1,*, Zhen-Jian Zhuo3,*, Jiaxiang Wang1, Jing He2, Lin Yang1, Da Zhang1, Pan Qin1 and Lizhao Yan1
1Department of Pediatric Surgery, the First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, Henan, China
2Department of Pediatric Surgery, Guangzhou Institute of Pediatrics, Guangzhou Women and Children’s Medical Center, Guangzhou Medical University, Guangzhou 510623, Guangdong, China
3School of Chinese Medicine, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong 999077, China
*These authors have contributed equally to this work
Jiao Zhang, email: firstname.lastname@example.org
Jing He, email: email@example.com
Keywords: neuroblastoma, CASC15, 6p22, polymorphism, susceptibility
Received: May 25, 2017 Accepted: July 31, 2017 Published: August 24, 2017
In this case-control study, we analyzed the association between three single nucleotide polymorphisms (SNPs) in the CASC15 gene (rs6939340 A>G, rs4712653 T>C, and rs9295536 C>A) and neuroblastoma susceptibility in the Guangdong and Henan populations of China. We genotyped and analyzed 118 cases and 281 control subjects from Henan province and combined them with previously published data from the Guangdong population. In the Henan population, only the rs6939340 G>A variant homozygote AA was associated with decreased neuroblastoma risk [AA vs. GG: adjusted odds ratio (OR) = 0.47, 95% confidence interval (CI) = 0.23-0.98; P=0.045]. All three polymorphisms, individually and in combination, were associated with decreased neuroblastoma susceptibility in the Guangdong population. Moreover, subjects carrying 1-3 of these protective genotypes had lower neuroblastoma susceptibility than non-carriers (adjusted OR=0.65, 95% CI=0.51-0.84, P=0.0007). These results show that all three genetic variants of CASC15 identified in a genome-wide association study (GWAS) decrease neuroblastoma risk in two distinct Chinese populations.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.